Adenovirus: The first effective in vivo gene delivery vector

Human Gene Therapy

Volumn 25, Issue 1, 2014, Pages 3-11

  Crystal, Ronald G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA 1 ANTITRYPSIN; BETA GALACTOSIDASE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; SONIC HEDGEHOG PROTEIN;

ADENOVIRUS INFECTION; ALPHA 1 ANTITRYPSIN DEFICIENCY; FOLLOW UP; HUMAN; IN VIVO GENE TRANSFER; NONHUMAN; RESPIRATORY EPITHELIUM; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRUS IMMUNITY;

ADENOVIRIDAE; ANIMALS; CLINICAL TRIALS AS TOPIC; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MICE; TREATMENT OUTCOME;

EID: 84892847173     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.2527     Document Type: Review

References (100)

1. Aguilar, L. K., Guzik, B. W., and Guilar-Cordova, E. (2011). Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development. J. Cell Biochem. 112, 1969-1977.
2. Ahi, Y. S., Bangari, D. S., and Mittal, S. K. (2011). Adenoviral vector immunity: its implications and circumvention strategies. Curr. Gene Ther. 11, 307-320.
3. Alemany, R. (2012). Chapter four-design of improved oncolytic adenoviruses. Adv. Cancer Res. 115, 93-114.
4. Aurisicchio, L., and Ciliberto, G. (2012). Genetic cancer vaccines: current status and perspectives. Expert Opin. Biol. Ther. 12, 1043-1058.
5. Bangari, D. S., and Mittal, S. K. (2006). Current strategies and future directions for eluding adenoviral vector immunity. Curr. Gene Ther. 6, 215-226.
6. Bangari, D. S., Shukla, S., and Mittal, S. K. (2005). Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture. Biochem. Biophys. Res. Commun. 327, 960-966.
7. Beatty, M. S., and Curiel, D. T. (2012). Chapter two-adenovirus strategies for tissue-specific targeting. Adv. Cancer Res. 115, 39-67.
8. Boyer, J. L., and Crystal, R. G. (2006). Genetic medicine strategies to protect against bioterrorism. Trans. Am. Clin. Climatol. Assoc. 117, 297-310.
9. Boyer, J. L., Kobinger, G., Wilson, J. M., et al. (2005). Adenovirus-based genetic vaccines for biodefense. Hum. Gene Ther. 16, 157-168.
10. Boyer, J. L., Sofer-Podesta, C., Ang, J., et al. (2010). Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid. Hum. Gene Ther. 21, 891-901.
11. Brunetti-Pierri, N., and Ng, P. (2011). Helper-dependent adenoviral vectors for liver-directed gene therapy. Hum. Mol. Genet. 20, R7-R13.
12. Cerullo, V., Koski, A., Vaha-Koskela, M., et al. (2012). Chapter eight-oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans. Adv. Cancer Res. 115, 265-318.
13. Chen, R. F., and Lee, C. Y. (2013). Adenoviruses types, cell receptors and local innate cytokines in adenovirus infection. Int. Rev. Immunol. [Epub ahead of print]; DOI: 10. 3109/ 08830185. 2013. 823420
14. Chiuchiolo, M. J., Boyer, J. L., Krause, A., et al. (2006). Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen. J. Infect. Dis. 194, 1249-1257.
15. Choi, I. K., and Yun, C. O. (2013). Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers. Cancer Gene Ther. 20, 70-76.
16. Crystal, R. G. (1990). Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J. Clin. Invest. 85, 1343-1352.
17. Crystal, R. G., McElvaney, N. G., Rosenfeld, M. A., et al. (1994). Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat. Genet. 8, 42-51.
18. Crystal, R. G., Harvey, B. G., Wisnivesky, J. P., et al. (2002). Analysis of risk factors for local delivery of low-and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum. Gene Ther. 13, 65-100.
19. Crystal, R. G., Kaminsky, S. M., Hackett, N. R., et al. (2012). Double-blinded, placebo-controlled, randomized gene therapy using surgery for vector delivery. Hum. Gene Ther. 23, 438-441.
20. De, B. P., Hackett, N. R., Crystal, R. G., et al. (2008). Rapid/ sustained anti-anthrax passive immunity mediated by coadministration of Ad/AAV. Mol. Ther. 16, 203-209.
21. De, B. P., Pagovich, O. E., Hicks, M. J., et al. (2013). Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity. Hum. Gene Ther. 24, 58-66.
22. Deisseroth, A., Tang, Y., Zhang, L., et al. (2013). TAA/ ecdCD40L adenoviral prime-protein boost vaccine for cancer and infectious diseases. Cancer Gene Ther. 20, 65-69.
23. Dharmapuri, S., Peruzzi, D., and Aurisicchio, L. (2009). Engineered adenovirus serotypes for overcoming anti-vector immunity. Expert Opin. Biol. Ther. 9, 1279-1287.
24. Dobbelstein, M. (2003). Viruses in therapy-royal road or dead end? Virus Res. 92, 219-221.
25. Duarte, S., Carle, G., Faneca, H., et al. (2012). Suicide gene therapy in cancer: where do we stand now? Cancer Lett. 324, 160-170.
26. Eager, R. M., and Nemunaitis, J. (2011). Clinical development directions in oncolytic viral therapy. Cancer Gene Ther. 18, 305-317.
27. Fukazawa, T., Matsuoka, J., Yamatsuji, T., et al. (2010). Adenovirus-mediated cancer gene therapy and virotherapy (Review). Int. J. Mol. Med. 25, 3-10.
28. Gadek, J. E., Hosea, S. W., Gelfand, J. A., et al. (1980). Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N. Engl. J. Med. 302, 542-546.
29. Gao, G. P., Yang, Y., and Wilson, J. M. (1996). Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J. Virol. 70, 8934-8943.
30. Garver, R. I., Jr., Chytil, A., Karlsson, S., et al. (1987). Production of glycosylated physiologically ''normal'' human alpha 1-antitrypsin by mouse fibroblasts modified by insertion of a human alpha 1-antitrypsin cDNA using a retroviral vector. Proc. Natl. Acad. Sci. USA 84, 1050-1054.
31. Ginsberg, H. S., ed. (1984). The Adenoviruses (Plenum Press, New York).
32. Hackett, N. R., and Crystal, R. G. (2008). Adenovirus vectors for gene therapy. In Gene Therapy: Therapeutic Mechanisms and Strategies, D. Lasic and N. S. Templeton, eds. (CRC Press, New York), pp. 39-68.
33. Hackett, N. R., Kaminsky, S. M., Sondhi, D., et al. (2000). Antivector and antitransgene host responses in gene therapy. Curr. Opin. Mol. Ther. 2, 376-382.
34. Hangalapura, B. N., Timares, L., Oosterhoff, D., et al. (2012). CD40-targeted adenoviral cancer vaccines: the long and winding road to the clinic. J. Gene Med. 14, 416-427.
35. Hartman, Z. C., Appledorn, D. M., and Amalfitano, A. (2008). Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res. 132, 1-14.
36. Harvey, B. G., Leopold, P. L., Hackett, N. R., et al. (1999). Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J. Clin. Invest. 104, 1245-1255.
37. Harvey, B. G., Maroni, J., O'Donoghue, K. A., et al. (2002). Safety of local delivery of low-and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum. Gene Ther. 13, 15-63.
38. Hashimoto, M., Boyer, J. L., Hackett, N. R., et al. (2005). Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity. Infect. Immun. 73, 6885-6891.
39. Hedley, S. J., Chen, J., Mountz, J. D., et al. (2006). Targeted and shielded adenovectors for cancer therapy. Cancer Immunol. Immunother. 55, 1412-1419.
40. Hicks, M. J., De, B. P., Rosenberg, J. B., et al. (2011). Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs. Mol. Ther. 19, 612-619.
41. Jaffe, H. A., Danel, C., Longenecker, G., et al. (1992). Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat. Genet. 1, 372-378.
42. Jooss, K., and Chirmule, N. (2003). Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy. Gene Ther. 10, 955-963.
43. Journal of Gene Medicine (2013). Gene Therapy Clinical Trials Worldwide. Available at www. wiley. com//legacy/wileychi/ genmed/clinical/ (accessed December 2013).
44. Kanerva, A., Mikheeva, G. V., Krasnykh, V., et al. (2002). Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin. Cancer Res. 8, 275-280.
45. Kasuya, K., Boyer, J. L., Tan, Y., et al. (2005). Passive immunotherapy for anthrax toxin mediated by an adenovirus expressing an anti-protective antigen single-chain antibody. Mol. Ther. 11, 237-244.
46. Kaufmann, J. K., and Nettelbeck, D. M. (2012). Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond. Trends Mol. Med. 18, 365-376.
47. Kerem, B., Rommens, J. M., Buchanan, J. A., et al. (1989). Identification of the cystic fibrosis gene: genetic analysis. Science 245, 1073-1080.
48. Khare, R., Chen, C. Y., Weaver, E. A., et al. (2011). Advances and future challenges in adenoviral vector pharmacology and targeting. Curr. Gene Ther. 11, 241-258.
49. Kochanek, S., Schiedner, G., and Volpers, C. (2001). Highcapacity ''gutless'' adenoviral vectors. Curr. Opin. Mol. Ther. 3, 454-463.
50. Koob, G., Hicks, M. J., Wee, S., et al. (2011). Anti-cocaine vaccine based on coupling a cocaine analog to a disrupted adenovirus. CNS Neurol. Disord. Drug Targets 10, 899-904.
51. Krause, A., and Worgall, S. (2011). Delivery of antigens by viral vectors for vaccination. Ther. Deliv. 2, 51-70.
52. Kushwah, R., Cao, H., and Hu, J. (2007). Potential of helperdependent adenoviral vectors in modulating airway innate immunity. Cell Mol. Immunol. 4, 81-89.
53. Lasaro, M. O., and Ertl, H. C. (2009). New insights on adenovirus as vaccine vectors. Mol. Ther. 17, 1333-1339.
54. Mack, C. A., Song, W. R., Carpenter, H., et al. (1997). Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum. Gene Ther. 8, 99-109.
55. Mack, C. A., Magovern, C. J., Budenbender, K. T., et al. (1998). Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. J. Vasc. Surg. 27, 699-709.
56. Mastrangeli, A., Harvey, B. G., Yao, J., et al. (1996). ''Seroswitch'' adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum. Gene Ther. 7, 79-87.
57. Matthews, Q. L. (2011). Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach. Mol. Pharm. 8, 3-11.
58. Matthews, K. S., Alvarez, R. D., and Curiel, D. T. (2009). Advancements in adenoviral based virotherapy for ovarian cancer. Adv. Drug Deliv. Rev. 61, 836-841.
59. Nemerow, G. R. (2009). A new link between virus cell entry and inflammation: adenovirus interaction with integrins induces specific proinflammatory responses. Mol. Ther. 17, 1490-1491.
60. Patel, S. R., Lee, L. Y., Mack, C. A., et al. (1999). Safety of direct myocardial administration of an adenovirus vector encoding vascular endothelial growth factor 121. Hum. Gene Ther. 10, 1331-1348.
61. Raper, S. E., Haskal, Z. J., Ye, X., et al. (1998). Selective gene transfer into the liver of non-human primates with E1-deleted, E2A-defective, or E1-E4 deleted recombinant adenoviruses. Hum. Gene Ther. 9, 671-679.
62. Riordan, J. R., Rommens, J. M., Kerem, B., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245, 1066-1073.
63. Rommens, J. M., Iannuzzi, M. C., Kerem, B., et al. (1989). Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245, 1059-1065.
64. Rosenfeld, M. A., Siegfried, W., Yoshimura, K., et al. (1991). Adenovirus-mediated transfer of a recombinant a1-antitrypsin gene to the lung epithelium in vivo. Science 252, 431-434.
65. Rosenfeld, M. A., Yoshimura, K., Trapnell, B. C., et al. (1992). In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68, 143-155.
66. Rosengart, T. K., Lee, L. Y., Patel, S. R., et al. (1999a). Sixmonth assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann. Surg. 230, 466-470.
67. Rosengart, T. K., Lee, L. Y., Patel, S. R., et al. (1999b). Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100, 468-474.
68. Rosengart, T. K., Bishawi, M. M., Halbreiner, M. S., et al. (2013). Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease. Hum. Gene Ther. 24, 203-208.
69. Russell, W. C. (2009). Adenoviruses: update on structure and function. J. Gen. Virol. 90, 1-20.
70. Russell, S. J., Peng, K. W., and Bell, J. C. (2012). Oncolytic virotherapy. Nat. Biotechnol. 30, 658-670.
71. Sack, B. K., and Herzog, R. W. (2009). Evading the immune response upon in vivo gene therapy with viral vectors. Curr. Opin. Mol. Ther. 11, 493-503.
72. Sato, N., Leopold, P. L., and Crystal, R. G. (1999). Induction of the hair growth phase in postnatal mice by localized transient expression of Sonic hedgehog. J. Clin. Invest. 104, 855-864.
73. Segura, M. M., Alba, R., Bosch, A., et al. (2008). Advances in helper-dependent adenoviral vector research. Curr. Gene Ther. 8, 222-235.
74. Seregin, S. S., and Amalfitano, A. (2009). Overcoming preexisting adenovirus immunity by genetic engineering of adenovirus-based vectors. Expert Opin. Biol. Ther. 9, 1521-1531.
75. Sharma, A., Li, X., Bangari, D. S., et al. (2009). Adenovirus receptors and their implications in gene delivery. Virus Res. 143, 184-194.
76. Shayakhmetov, D. M. (2010). Virus infection recognition and early innate responses to non-enveloped viral vectors. Viruses 2, 244-261.
77. Short, J. J., and Curiel, D. T. (2009). Oncolytic adenoviruses targeted to cancer stem cells. Mol. Cancer Ther. 8, 2096-2102.
78. Smith, J. G., Wiethoff, C. M., Stewart, P. L., et al. (2010). Adenovirus. Curr. Top. Microbiol. Immunol. 343, 195-224.
79. Sofer-Podesta, C., Ang, J., Hackett, N. R., et al. (2009). Adenovirus-mediated delivery of an anti-V antigen monoclonal antibody protects mice against a lethal Yersinia pestis challenge. Infect. Immun. 77, 1561-1568.
80. Stone, D., and Lieber, A. (2006). New serotypes of adenoviral vectors. Curr. Opin. Mol. Ther. 8, 423-431.
81. Suzuki, M., Singh, R., Moore, M. A., et al. (1998). Similarity of strain-and route-dependent murine responses to an adenovirus vector using the homologous thrombopoietin cDNA as the reporter genes. Hum. Gene Ther. 9, 1223-1231.
82. Tagawa, M., Kawamura, K., Ueyama, T., et al. (2008). Cancer therapy with local oncolysis and topical cytokine secretion. Front. Biosci. 13, 2578-2587.
83. Tan, Y., Hackett, N. R., Boyer, J. L., et al. (2003). Protective immunity evoked against anthrax lethal toxin after a single intramuscular administration of an adenovirus-based vaccine encoding humanized protective antigen. Hum. Gene Ther. 14, 1673-1682.
84. Thaci, B., Ulasov, I. V., Wainwright, D. A., et al. (2011). The challenge for gene therapy: innate immune response to adenoviruses. Oncotarget 2, 113-121.
85. Thacker, E. E., Timares, L., and Matthews, Q. L. (2009). Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert Rev. Vaccines 8, 761-777.
86. Van Blarcom, T. J., Sofer-Podesta, C., Ang, J., et al. (2010). Affinity maturation of an anti-V antigen IgG expressed in situ through adenovirus gene delivery confers enhanced protection against Yersinia pestis challenge. Gene Ther. 17, 913-921.
87. Vetrini, F., and Ng, P. (2011). Liver-directed gene therapy with helper-dependent adenoviral vectors: current state of the art and future challenges. Curr. Pharm. Des. 17, 2488-2499.
88. Wee, S., Hicks, M. J., De, B. P., et al. (2012). Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects. Neuropsychopharmacology 37, 1083-1091.
89. Weitzman, M. D. (2005). Functions of the adenovirus E4 proteins and their impact on viral vectors. Front. Biosci. 10, 1106-1117.
90. Wewers, M. D., Casolaro, M. A., Sellers, S. E., et al. (1987). Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N. Engl. J. Med. 316, 1055-1062.
91. Wilson, J. M. (1996). Adenoviruses as gene-delivery vehicles. N. Engl. J. Med. 334, 1185-1187.
92. Wolfrum, N., and Greber, U. F. (2013). Adenovirus signalling in entry. Cell Microbiol. 15, 53-62.
93. Worgall, S., Leopold, P. L., Wolff, G., et al. (1997). Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract. Hum. Gene Ther. 8, 1675-1684.
94. Wu, Q., Xia, D., Carlsen, S., et al. (2005). Adenovirus-mediated transgene-engineered dendritic cell vaccine of cancer. Curr. Gene Ther. 5, 237-247.
95. Yang, Y., Nunes, F. A., Berencsi, K., et al. (1994). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 91, 4407-4411.
96. Yang, Y., Jooss, K. U., Su, Q., et al. (1996). Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 3, 137-144.
97. Yang, T. C., Millar, J. B., Grinshtein, N., et al. (2007). T-cell immunity generated by recombinant adenovirus vaccines. Expert Rev. Vaccines 6, 347-356.
98. Zabner, J., Couture, L. A., Gregory, R. J., et al. (1993). Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 75, 207-216.
99. Zaiss, A. K., Machado, H. B., and Herschman, H. R. (2009). The influence of innate and pre-existing immunity on adenovirus therapy. J. Cell Biochem. 108, 778-790.
100. Zuckerman, J. B., Robinson, C. B., McCoy, K. S., et al. (1999). A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Hum. Gene Ther. 10, 2973-2985.